AbbVie's top line is stable post-Humira, with Skyrizi and Rinvoq driving growth, but margin recovery remains uncertain and slow. Pipeline and acquisitions support long-term growth, but macro risks like IRA pricing and pharma tariffs could pressure margins further. Dividend yield is attractive, but potential recent cash flow weakness raises questions about sustainability if not transitory; capital allocation needs watching.
Skyrizi and Rinvoq are rapidly replacing Humira, generating over $5 billion in Q1 2025 alone. From migraine to Parkinson's and obesity, AbbVie is building dominant franchises across multiple high-growth areas. With 42% operating margins, $20B in free cash flow, and a 3.4% dividend yield, AbbVie offers both growth and stability.
AbbVie is undervalued, trading at under 16x 2025 earnings, despite robust EPS growth, a strong pipeline, and successful Humira diversification. Skyrizi and Rinvoq are driving immunology revenue, expected to surpass $15 billion by 2027, with neuroscience and oncology portfolios also showing strong growth. AbbVie has delivered 11 consecutive years of dividend increases, with a 7.23% five-year CAGR and a current yield of 3.43%, rewarding shareholders consistently.
![]() 4AB 2 months ago | Other | €1.42 Per Share |
![]() 4AB 5 months ago | Other | €1.42 Per Share |
![]() 4AB 8 months ago | Other | €1.34 Per Share |
![]() 4AB 11 months ago | Other | €1.34 Per Share |
![]() 4AB 12 Apr 2024 | Other | €1.34 Per Share |
23 Jul 2025 (37 Days) Date | | - Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | - EPS |
25 Oct 2024 Date | | - Cons. EPS | - EPS |
![]() 4AB 2 months ago | Other | €1.42 Per Share |
![]() 4AB 5 months ago | Other | €1.42 Per Share |
![]() 4AB 8 months ago | Other | €1.34 Per Share |
![]() 4AB 11 months ago | Other | €1.34 Per Share |
![]() 4AB 12 Apr 2024 | Other | €1.34 Per Share |
23 Jul 2025 (37 Days) Date | | - Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | - EPS |
25 Oct 2024 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Mr. Robert A. Michael CPA CEO | XBER Exchange | US00287Y1091 ISIN |
US Country | 55,000 Employees | 15 Apr 2025 Last Dividend | - Last Split | 2 Jan 2013 IPO Date |
AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.